 |
|
Psoralen Bath Plus UV-A TherapyPossibilities and Limitations
Matthias Lüftl, MD;
Klaus Degitz, MD;
Gerd Plewig, MD;
Martin Röcken, MD
Arch Dermatol. 1997;133(12):1597-1603.
Abstract
Oral psoralen plus UV-A (PUVA) therapy was originally developed for the treatment of vitiligo.1,2 With the introduction of potent UV-A irradiation sources between 1972 and 1974, UV-A irradiation following psoralen application was found to be a highly efficient therapy for proriasis.3-5 The acronym PUVA was created and the potential use of PUVA was investigated in a large spectrum of different inflammatory and neoplastic skin diseases.6-8 Psoralen plus UV-A has profoundly influenced the therapeutic concepts of dermatology, as demonstrated in the recent review by Honig et al.8 An alternative approach, psoralen bath plus UV-A therapy (PUVA bath therapy) that avoids the adverse effects associated with oral PUVA therapy has increasingly been used during recent years. Psoralen bath plus UV-A therapy is not simply a technical variant of photochemotherapy; it is obviously superior to oral PUVA, at least for some indications, and it has considerably enlarged the spectrum of diseases responsive to photochemotherapy.
Author Affiliations
From the Department of Dermatology, Ludwig-Maximilians-University of Munich, Munich, Germany.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Bath PUVA and Saltwater Baths Followed by UV-B Phototherapy as Treatments for Psoriasis: A Randomized Controlled Trial
Schiener et al.
Arch Dermatol 2007;143:586-596.
ABSTRACT
| FULL TEXT
Treatment of Psoriasis With Calcipotriene Plus Psoralen-UV-A-Bath Therapy
Grundmann-Kollmann et al.
Arch Dermatol 1999;135:861-862.
FULL TEXT
Oral Psoralen-UV-A for Systemic Scleroderma
Hofer et al.
Arch Dermatol 1999;135:603-604.
FULL TEXT
Bath Psoralen-UV-A Therapy for Persistent Grover Disease
Luftl et al.
Arch Dermatol 1999;135:606-607.
FULL TEXT
Variations of PUVA: Practical and Effective?
Morison
Arch Dermatol 1998;134:1286-1288.
FULL TEXT
|
